234 related articles for article (PubMed ID: 29753531)
21. Relationship of Hippocampal Volume to Amyloid Burden across Diagnostic Stages of Alzheimer's Disease.
Trzepacz PT; Hochstetler H; Yu P; Castelluccio P; Witte MM; Dell'Agnello G; Degenhardt EK;
Dement Geriatr Cogn Disord; 2016; 41(1-2):68-79. PubMed ID: 26625159
[TBL] [Abstract][Full Text] [Related]
22. Genome-wide interaction study of brain beta-amyloid burden and cognitive impairment in Alzheimer's disease.
Roostaei T; Nazeri A; Felsky D; De Jager PL; Schneider JA; Pollock BG; Bennett DA; Voineskos AN;
Mol Psychiatry; 2017 Feb; 22(2):287-295. PubMed ID: 27021820
[TBL] [Abstract][Full Text] [Related]
23. Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia.
Trzepacz PT; Yu P; Sun J; Schuh K; Case M; Witte MM; Hochstetler H; Hake A;
Neurobiol Aging; 2014 Jan; 35(1):143-51. PubMed ID: 23954175
[TBL] [Abstract][Full Text] [Related]
24. Empirically Defining Trajectories of Late-Life Cognitive and Functional Decline.
Hochstetler H; Trzepacz PT; Wang S; Yu P; Case M; Henley DB; Degenhardt E; Leoutsakos JM; Lyketsos CG
J Alzheimers Dis; 2016; 50(1):271-82. PubMed ID: 26639960
[TBL] [Abstract][Full Text] [Related]
25. Focal hemosiderin deposits and β-amyloid load in the ADNI cohort.
Kantarci K; Gunter JL; Tosakulwong N; Weigand SD; Senjem MS; Petersen RC; Aisen PS; Jagust WJ; Weiner MW; Jack CR;
Alzheimers Dement; 2013 Oct; 9(5 Suppl):S116-23. PubMed ID: 23375568
[TBL] [Abstract][Full Text] [Related]
26. Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a 'European ADNI study'.
Galluzzi S; Marizzoni M; Babiloni C; Albani D; Antelmi L; Bagnoli C; Bartres-Faz D; Cordone S; Didic M; Farotti L; Fiedler U; Forloni G; Girtler N; Hensch T; Jovicich J; Leeuwis A; Marra C; Molinuevo JL; Nobili F; Pariente J; Parnetti L; Payoux P; Del Percio C; Ranjeva JP; Rolandi E; Rossini PM; Schönknecht P; Soricelli A; Tsolaki M; Visser PJ; Wiltfang J; Richardson JC; Bordet R; Blin O; Frisoni GB;
J Intern Med; 2016 Jun; 279(6):576-91. PubMed ID: 26940242
[TBL] [Abstract][Full Text] [Related]
27. Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography.
Palmqvist S; Mattsson N; Hansson O;
Brain; 2016 Apr; 139(Pt 4):1226-36. PubMed ID: 26936941
[TBL] [Abstract][Full Text] [Related]
28. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
Portelius E; Zetterberg H; Skillbäck T; Törnqvist U; Andreasson U; Trojanowski JQ; Weiner MW; Shaw LM; Mattsson N; Blennow K;
Brain; 2015 Nov; 138(Pt 11):3373-85. PubMed ID: 26373605
[TBL] [Abstract][Full Text] [Related]
29. Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease.
Edmonds EC; Delano-Wood L; Galasko DR; Salmon DP; Bondi MW;
J Alzheimers Dis; 2015; 47(1):231-42. PubMed ID: 26402771
[TBL] [Abstract][Full Text] [Related]
30. Inter-rater variability of visual interpretation and comparison with quantitative evaluation of
Yamane T; Ishii K; Sakata M; Ikari Y; Nishio T; Ishii K; Kato T; Ito K; Senda M;
Eur J Nucl Med Mol Imaging; 2017 May; 44(5):850-857. PubMed ID: 27966045
[TBL] [Abstract][Full Text] [Related]
31. The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans.
Kang JH; Korecka M; Figurski MJ; Toledo JB; Blennow K; Zetterberg H; Waligorska T; Brylska M; Fields L; Shah N; Soares H; Dean RA; Vanderstichele H; Petersen RC; Aisen PS; Saykin AJ; Weiner MW; Trojanowski JQ; Shaw LM;
Alzheimers Dement; 2015 Jul; 11(7):772-91. PubMed ID: 26194312
[TBL] [Abstract][Full Text] [Related]
32. Sample Size Estimation for Alzheimer's Disease Trials from Japanese ADNI Serial Magnetic Resonance Imaging.
Fujishima M; Kawaguchi A; Maikusa N; Kuwano R; Iwatsubo T; Matsuda H; ;
J Alzheimers Dis; 2017; 56(1):75-88. PubMed ID: 27911297
[TBL] [Abstract][Full Text] [Related]
33. The Relationship of Brain Amyloid Load and APOE Status to Regional Cortical Thinning and Cognition in the ADNI Cohort.
Li C; Loewenstein DA; Duara R; Cabrerizo M; Barker W; Adjouadi M;
J Alzheimers Dis; 2017; 59(4):1269-1282. PubMed ID: 28731444
[TBL] [Abstract][Full Text] [Related]
34. Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: findings from the Alzheimer's Disease Neuroimaging Initiative.
Chen K; Langbaum JB; Fleisher AS; Ayutyanont N; Reschke C; Lee W; Liu X; Bandy D; Alexander GE; Thompson PM; Foster NL; Harvey DJ; de Leon MJ; Koeppe RA; Jagust WJ; Weiner MW; Reiman EM;
Neuroimage; 2010 Jun; 51(2):654-64. PubMed ID: 20202480
[TBL] [Abstract][Full Text] [Related]
35. The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022.
Veitch DP; Weiner MW; Miller M; Aisen PS; Ashford MA; Beckett LA; Green RC; Harvey D; Jack CR; Jagust W; Landau SM; Morris JC; Nho KT; Nosheny R; Okonkwo O; Perrin RJ; Petersen RC; Rivera Mindt M; Saykin A; Shaw LM; Toga AW; Tosun D;
Alzheimers Dement; 2024 Jan; 20(1):652-694. PubMed ID: 37698424
[TBL] [Abstract][Full Text] [Related]
36. Application of the IWG-2 Diagnostic Criteria for Alzheimer's Disease to the ADNI.
Wang HF; Tan L; Cao L; Zhu XC; Jiang T; Tan MS; Liu Y; Wang C; Tsai RM; Jia JP; Yu JT;
J Alzheimers Dis; 2016; 51(1):227-36. PubMed ID: 26836176
[TBL] [Abstract][Full Text] [Related]
37. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
[TBL] [Abstract][Full Text] [Related]
38. Cognitive Composites Domain Scores Related to Neuroimaging Biomarkers within Probable-Amnestic Mild Cognitive Impairment-Storage Subtype.
Espinosa A; Alegret M; Pesini P; Valero S; Lafuente A; Buendía M; San José I; Ibarria M; Tejero MA; Giménez J; Ruiz S; Hernández I; Pujadas F; Martínez-Lage P; Munuera J; Arbizu J; Tárraga L; Hendrix SB; Ruiz A; Becker JT; Landau SM; Sotolongo-Grau O; Sarasa M; Boada M; ;
J Alzheimers Dis; 2017; 57(2):447-459. PubMed ID: 28269787
[TBL] [Abstract][Full Text] [Related]
39. Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative.
Jack CR; Bernstein MA; Borowski BJ; Gunter JL; Fox NC; Thompson PM; Schuff N; Krueger G; Killiany RJ; Decarli CS; Dale AM; Carmichael OW; Tosun D; Weiner MW;
Alzheimers Dement; 2010 May; 6(3):212-20. PubMed ID: 20451869
[TBL] [Abstract][Full Text] [Related]
40. Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
J Alzheimers Dis; 2018; 62(1):399-408. PubMed ID: 29439345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
